Albumin-binding MR blood pool agents as MRI contrast agents in an intracranial mouse glioma model

✍ Scribed by Kofi Adzamli; Dmitriy A. Yablonskiy; Michael R. Chicoine; Eun Kyung Won; Karen P. Galen; Michael C. Zahner; Thomas A. Woolsey; Joseph J.H. Ackerman

• Publisher: John Wiley and Sons
• Year: 2003
• Tongue: English
• Weight: 312 KB
• Volume: 49
• Category: Article
• ISSN: 0740-3194
• DOI: 10.1002/mrm.10382

✦ Synopsis

Intravenous MRI contrast agents are commonly used to improve the detection of intracranial tumors and other central nervous system (CNS) lesions for diagnosis and treatment planning. Two small-molecule, albumin-binding blood pool contrast agents (MP-2269 and MS-325) of potential clinical significance were evaluated at 1.5 Tesla in a mouse glioma model and compared with an extracellular contrast agent (OptiMARK). Tumor image contrast was significantly enhanced and long-lived following administration of 30 micromole/kg of the blood pool agents: specifically, contrast enhancement peaked slowly at 25-30 min following administration, remained constant for >3 hr, and returned to baseline within 20 hr. Comparable but "transient" enhancement was achieved using 100 micromole/kg OptiMARK: specifically, contrast enhancement peaked rapidly at 2-5 min following administration and then declined over 40 min. The blood pool contrast agents demonstrated an approximately threefold increased dose-effectiveness and a lengthened window of tumor contrast enhancement in comparison to commonly available extracellular contrast agents. This demonstrates the potential of alternative contrast-enhanced (CE) MRI examination protocols for tumor detection.